Personalizing Treatment of Early-Stage Breast Cancer
Emiel J. Rutgers, MD, from the Netherlands Cancer Institute, describes the personalization of treatment for patients with early-stage breast cancer.
Emiel J. Rutgers, MD, surgical oncologist, Netherlands Cancer Institute, Amsterdam, describes the personalization of treatment for patients with early-stage breast cancer.
Clinical Pearls
In this group of patients, a physician must look at the results of a sentinel node biopsy and consider the primary tumor characteristics. If there is low tumor involvement, a physician would most likely determine that no treatment of the axial is adequate. If a patient has more tumor involvement in the sentinel nodes and larger tumor burden in the breast, elective treatment of the axilla with radiotherapy is a good strategy.
- In patients with low tumor involvement, no treatment of the axilla is adequate
- In patients with more tumor involvement in the sentinel nodes, elective treatment of the axilla with radiotherapy is a good strategy
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
